相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。5-Aza-2′-deoxycytidine increases hypoxia tolerance-dependent autophagy in mouse neuronal cells by initiating the TSC1/mTOR pathway
Ruifang Qi et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Cancer and ER stress: Mutual crosstalk between autophagy, oxidative stress and inflammatory response
Yuning Lin et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Role and mechanism of decitabine combined with tyrosine kinase inhibitors in advanced chronic myeloid leukemia cells
Li-Cai Jiang et al.
ONCOLOGY LETTERS (2017)
Downregulation of TIGAR sensitizes the antitumor effect of physapubenolide through increasing intracellular ROS levels to trigger apoptosis and autophagosome formation in human breast carcinoma cells
Ting Ma et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Autophagy and multidrug resistance in cancer
Ying-Jie Li et al.
CHINESE JOURNAL OF CANCER (2017)
Improving cancer immunotherapy with DNA methyltransferase inhibitors
Mohammad H. Saleh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Decitabine and 5-azacitidine both alleviate LPS induced ARDS through anti-inflammatory/antioxidant activity and protection of glycocalyx and inhibition of MAPK pathways in mice
Xiao Huang et al.
BIOMEDICINE & PHARMACOTHERAPY (2016)
Recent insights into the function of autophagy in cancer
Ravi Amaravadi et al.
GENES & DEVELOPMENT (2016)
TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia
Sixuan Qian et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Combination treatment with decitabine and ionizing radiation enhances tumor cells susceptibility of T cells
Cheol-Hun Son et al.
SCIENTIFIC REPORTS (2016)
ROS and Autophagy: Interactions and Molecular Regulatory Mechanisms
Lulu Li et al.
CELLULAR AND MOLECULAR NEUROBIOLOGY (2015)
Clinical Results of Hypomethylating Agents in AML Treatment
Marjan Cruijsen et al.
JOURNAL OF CLINICAL MEDICINE (2015)
Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
Haiyang Yun et al.
HAEMATOLOGICA (2014)
Oxidative stress: the mitochondria-dependent and mitochondria-independent pathways of apoptosis
Krishnendu Sinha et al.
ARCHIVES OF TOXICOLOGY (2013)
Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia
E. H. Estey
LEUKEMIA (2013)
Molecular crosstalk between the proteasome, aggresomes and autophagy: Translational potential and clinical implications
James J. Driscoll et al.
CANCER LETTERS (2012)
Decitabine, a DNA methyltransferase inhibitor, induces apoptosis in human leukemia cells through intracellular reactive oxygen species generation
Dong Yeok Shin et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2012)
Deconvoluting the context-dependent role for autophagy in cancer
Eileen White
NATURE REVIEWS CANCER (2012)
Sustained exposure to the DNA demethylating agent, 2′-deoxy-5-azacytidine, leads to apoptotic cell death in chronic myeloid leukemia by promoting differentiation, senescence, and autophagy
Michael Schnekenburger et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer
Alberto J. Montero et al.
DRUGS (2011)
Regulation of autophagy by ROS: physiology and pathology
Ruth Scherz-Shouval et al.
TRENDS IN BIOCHEMICAL SCIENCES (2011)
Chronic Myeloid Leukemia Patients Sensitive and Resistant to Imatinib Treatment Show Different Metabolic Responses
Jiye A et al.
PLOS ONE (2010)
Evolution of decitabine development - Accomplishments, ongoing investigations, and future strategies
Elias Jabbour et al.
CANCER (2008)
Upregulation of the NADPH oxidase NOX4 by TGF-beta in hepatocytes is required for its pro-apoptotic activity
Irene Carmona-Cuenca et al.
JOURNAL OF HEPATOLOGY (2008)
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth
Heather R. Christofk et al.
NATURE (2008)
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia
Yasuhiro Oki et al.
CANCER (2007)
TIGAR, a p53-inducible regulator of glycolysis and apoptosis
Karim Bensaad et al.
CELL (2006)
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies
JPJ Issa et al.
BLOOD (2004)
Biology of chronic myelogenous leukemia-signaling pathways of initiation and transformation
JV Melo et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2004)
分享论文
